Oligodendrocytes associate with axons to establish myelin and provide metabolic support to neurons. In the spinal cord of amyotrophic lateral sclerosis (ALS) mice, oligodendrocytes downregulate transporters that transfer glycolytic substrates to neurons and oligodendrocyte progenitors (NG2 + cells) exhibit enhanced proliferation and differentiation, although the cause of these changes in oligodendroglia is unknown. We found extensive degeneration of gray matter oligodendrocytes in the spinal cord of SOD1 (G93A) ALS mice prior to disease onset. Although new oligodendrocytes were formed, they failed to mature, resulting in progressive demyelination. Oligodendrocyte dysfunction was also prevalent in human ALS, as gray matter demyelination and reactive changes in NG2 + cells were observed in motor cortex and spinal cord of ALS patients. Selective removal of mutant SOD1 from oligodendroglia substantially delayed disease onset and prolonged survival in ALS mice, suggesting that ALS-linked genes enhance the vulnerability of motor neurons and accelerate disease by directly impairing the function of oligodendrocytes.
a r t I C l e S ALS is an adult-onset neurodegenerative disease characterized by progressive muscle weakness and eventual paralysis. Although disease culminates in the degeneration of motor neurons, non-neuronal cells such as astrocytes and microglia are critical for the pathogenic process of ALS [1] [2] [3] [4] . ALS-linked genes such as Sod1 are expressed in glia and motor neurons, and glial cell dysfunction appears to exacerbate injury to motor neurons, as selective removal of mutant SOD1 from subsets of glia slows disease progression 2, 3 . However, the vulnerability of distinct populations of glial cells to disease-induced stress and the contributions of these alterations to the pathogenesis of ALS are not well understood.
Degeneration of motor neurons in the spinal cord is associated with reactive changes in surrounding glia that include cellular hypertrophy and enhanced proliferation. In particular, recent studies have found that the behavior of NG2 + glial cells, a distinct, widely distributed class of progenitor cells that have the capacity to differentiate into oligodendrocytes, is markedly altered in the spinal cord of a mouse model of ALS (SOD1 (G93A)) 5, 6 . By end stage of disease, NG2 + cells exhibit the highest rate of proliferation of any cell type in the spinal cord of these mice, and their differentiation into oligodendrocytes is markedly enhanced 5 , suggesting that there may be a progressive dysfunction of oligodendrocytes in ALS.
In addition to their role in forming myelin, there is emerging evidence that oligodendrocytes provide crucial metabolic support to neurons 7, 8 . The monocarboxylic acid transporter 1 (MCT1), a transporter that motor neurons depend on for transfer of glycolytic substrates 9, 10 , is expressed predominantly by oligodendrocytes 9, 11 and is downregulated in the motor cortex of ALS patients and the spinal cord of SOD1 (G93A) mice 9 . Together, these abnormalities in the oligodendrocyte lineage in ALS may affect motor neuron survival; however, the cause of the enhanced proliferation and differentiation of oligodendrocyte progenitors in SOD1 (G93A) mice, and the extent of oligodendrocyte abnormalities in human ALS 12, 13 are uncertain.
Using in vivo genetic fate tracing of oligodendrocytes and their progenitors, we found an extensive, progressive degeneration of oligodendrocytes in the spinal cord of SOD1 (G93A) mice, with less than half of the oligodendrocytes produced in first postnatal month surviving by end stage of disease. Mobilization of oligodendrocyte progenitors occurred first in the ventral gray matter, where motor neurons are located, before behavioral manifestation of disease; however, newly formed oligodendrocytes in this region exhibited abnormal morphologies and failed to fully differentiate. Dysfunction of gray matter oligodendrocytes was also prevalent in human ALS, as reactive changes in NG2 + cells and demyelination were observed in the gray matter of the ventral spinal cord and motor cortex of ALS patients. Genetic deletion of mutant human SOD1 (G37R) from NG2 + cells and their oligodendrocyte progeny in mice substantially delayed disease onset and prolonged survival, indicating that expression of this ALS-linked gene in the oligodendrocyte lineage accelerates motor neuron degeneration. The progressive loss of gray matter oligodendrocytes, and failure to restore these crucial cells, may accelerate disease progression in ALS by depriving motor neurons of essential metabolic support.
RESULTS

Enhanced proliferation of NG2 + cells in young ALS mice
The progressive loss of motor neurons in SOD1 (G93A) mice is accompanied by prominent changes in the behavior of NG2 + cells 5 . a r t I C l e S By end stage of disease, their proliferation rate is 20-fold higher than in wild-type mice 5 , and they comprise the majority of actively dividing cells in the spinal cord 5, 6 . However, the cause of this enhanced proliferation in ALS is unknown. To determine when and where NG2 + cells first exhibit this altered behavior, we examined the spatiotemporal profile of NG2 + cell proliferation over the course of disease. Mice were administered BrdU for 5 d and cumulative BrdU incorporation was measured in lumbar spinal cord ( Fig. 1a,b and Supplementary Fig. 1a ). In wild-type mice, the number of BrdU + NG2 + cells declined with age in all of the regions that were examined (P < 0.001, one-way ANOVA; Fig. 1c-e ), following the developmental decline in the generation of oligodendrocytes from these progenitors 5, 14, 15 . However, in SOD1 (G93A) mice, NG2 + cells sustained high rates of proliferation into adulthood ( Fig. 1c-e ). Moreover, unlike the uniform decline in proliferation in wild-type mice, NG2 + cells in SOD1 (G93A) mice exhibited regional differences in their response. Enhanced proliferation was most prominent in ventral gray matter, where their rate of division was elevated 2.3-fold compared with wildtype mice by postnatal day 60 (P60, P < 0.001, Student's t test), before SOD1 (G93A) mice show disease symptoms 16 , and 12.9-fold by P95 (P < 0.0005), after they exhibit muscle weakness and tremor 17 . NG2 + cells in ventral white and dorsal gray matter of ALS mice eventually exhibited enhanced proliferation, although it occurred later and the magnitude of increased cell division was lower than in ventral gray matter ( Fig. 1c-e ). Thus, NG2 + cells in SOD1 (G93A) mice display abnormal behavior in ventral gray matter before behavioral manifestation of disease.
Despite the enhanced generation of NG2 + cells in early stages of disease, their density was not significantly altered before end stage (P > 0.05; Fig. 1f-h ), suggesting that they are continually removed through death or differentiation. To determine the fate of NG2 + cells at early stages of disease, we carried out genetic lineage tracing with Pdgfra-creER; Z/EG mice 5 . After breeding to SOD1 (G93A) mice, we administered 4-hydroxytamoxifen (4HT) at P30 or P60 to induce EGFP expression in cohorts of NG2 + cells, and identified EGFP + cells in lumbar spinal cord 15-60 d later ( Fig. 2a and Supplementary  Fig. 1b,c) . Consistent with the regional differences in NG2 + cell proliferation, more EGFP + cells were observed in ventral gray matter by P90 in SOD1 (G93A) mice ( Fig. 2b and Supplementary Fig. 1d-f) , whereas the number of EGFP + cells in other areas was not significantly increased relative to controls (P > 0.05). However, by end stage, EGFP + cell density in SOD1 (G93A) mice was higher than controls in all of the regions examined, with ventral gray matter exhibiting the greatest accumulation of NG2 + cell progeny ( Supplementary  Fig. 1d-f ). As the number of EGFP + cells should remain constant if they have an equal probability of dividing or dying, these results suggest that the enhanced proliferation of NG2 + cells is not induced solely by accelerated death of these progenitors.
Oligodendrogenesis without oligodendrocyte accumulation NG2 + cells in the spinal cord of end stage SOD1 (G93A) mice not only proliferate more rapidly, but also differentiate more frequently into oligodendrocytes 5 . To determine where and when this increase in oligodendrogenesis occurs, we followed the appearance of EGFP + cells in Pdgfra-creER; Z/EG; SOD1 (G93A) and Pdgfra-creER; Z/EG mice that were immunoreactive to antibody to APC (CC1), a feature of mature oligodendrocytes. Consistent with the early maturation of myelinated tracts in the spinal cord 18 , few oligodendrocytes (EGFP + CC1 + cells) were generated from P60-120 in controls ( Fig. 2c-h) . In contrast, there was a marked increase in newly generated oligodendrocytes in ventral gray matter of SOD1 (G93A) mice (P < 0.001, one-way ANOVA; Fig. 2c-f ); there were 10.9-fold more EGFP + CC1 + cells in this region relative to wild-type mice 60 d after labeling (P < 0.0005, Student's t test; Fig. 2f ).
An increase in EGFP + oligodendrocytes also was observed in ventral white matter at P90 and end stage in ALS mice, although this increase was smaller than in ventral gray matter (Fig. 2g) , and there was no significant change (P > 0.05) in EGFP + oligodendrocytes relative to control in dorsal gray matter ( Fig. 2g,h) . As the fate of only a small fraction (~15%) of NG2 + cells was followed in these experiments, the total number of oligodendrocytes generated during this period is expected to be much greater (by ~6-7-fold). Despite this marked increase in oligodendrogenesis, the overall density of oligodendrocytes in the spinal cord of SOD1 (G93A) mice at end stage was unchanged relative to wild type ( Fig. 2i) . These results suggest that there must be a concomitant loss of oligodendrocytes with advancing disease.
Degeneration of early-born oligodendrocytes in ALS mice
To determine the extent of oligodendrocyte survival during the course of disease, we performed genetic fate tracing of oligodendrocytes using Plp1-creER; ROSA26-EYFP; SOD1 (G93A) and Plp1-creER; ROSA26-EYFP mice ( Fig. 3a,b ). Administration of 4HT at P35 resulted in labeling of 15-25% of oligodendrocytes in ventral gray and white matter regions of the spinal cord. Although Cre-mediated recombination npg a r t I C l e S occurs in some NG2 + cells in the brains of Plp1-creER; ROSA26-EYFP mice 19 , EYFP was not expressed by these progenitors in the spinal cord of either control or SOD1 (G93A) mice ( Supplementary Fig. 2) , indicating that this approach can be used to track the survival of spinal cord oligodendrocytes in vivo. Quantitative analysis of spinal cords sampled at early time points revealed that the number of EYFP + oligodendrocytes increased gradually for the first 2 weeks after 4HT administration in both control and SOD1 (G93A) mice 19 , and initial labeling of these cells was substantially higher in SOD1 (G93A) mice than in control mice in ventral gray matter (at P35+15), possibly reflecting enhanced activity of the Plp1 transgene promoter. To allow direct comparison of oligodendrocyte survival between control and SOD1 (G93A) mice, we normalized the number of EYFP-labeled oligodendrocytes in each cohort to that observed at P35+15, when oligodendrocyte labeling in SOD1 (G93A) mice was near maximum ( Fig. 3c,d) . In control mice, there was a small increase in EYFP + oligodendrocytes in lumbar spinal cord (EYFP + CC1 + Olig2 + ) 40 and 70 d after initial labeling (at P50) ( Fig. 3c) , indicating a modest, but continuous, labeling of oligodendrocytes during this period. In contrast, the number of EYFP + oligodendrocytes in SOD1 (G93A) mice was reduced by 22% at 40 d after labeling (P < 0.05, one-way ANOVA with Tukey; Fig. 3c ). This loss was progressive, as the number of labeled oligodendrocytes was reduced by 65% at end stage (P < 0.0005, one-way ANOVA; Fig. 3c,e ). Moreover, as expected from the regional npg a r t I C l e S difference in NG2 + cell proliferation and oligodendrogenesis, loss of early-born oligodendrocytes in ALS mice was most prominent in ventral gray matter ( Fig. 3c,d) . These results indicate that there is already pronounced degeneration of oligodendrocytes in ventral gray matter near motor neurons when mice first exhibit overt signs of disease. If oligodendrocytes degenerate in the spinal cord of ALS mice, other indications of cell death should be visible. Indeed, some EGFPexpressing oligodendrocytes were immunopositive for activated caspase-3 in the spinal cord of end stage Mobp-EGFP; SOD1 (G93A) mice ( Fig. 4a) , in which only mature oligodendrocytes express EGFP (Supplementary Fig. 3) . Moreover, we observed dense cell clusters consisting of EGFP + oligodendrocytes surrounded by activated microglial cells at P90 in ventral gray matter (Fig. 4b) . Consistent with the death of early born oligodendrocytes observed through genetic fate tracing, we found similar microglia-oligodendrocyte (EYFP + ) aggregates in P90 Plp1-creER; ROSA26-EYFP; SOD1 (G93A) mice, in which oligodendrocytes were labeled at P35 (P35+55) (Fig. 4c) ; however, we did not find microglial clustering near GFAP + astrocytes (Fig. 4c) . Given that microglia are attracted to apoptotic cells 20 , the presence of these cell aggregates may indicate that mature oligodendrocytes in this region are dying via apoptotic death.
Widespread axonal degeneration can lead to loss of oligodendrocytes and reactive changes in their progenitors 21, 22 , raising the possibility that degeneration of gray matter oligodendrocytes in ALS mice is secondary to motor neuron degeneration. To address whether loss of motor neurons is sufficient to induce mobilization of NG2 + cells, we partially ablated motor neurons by injecting ricin into the sciatic nerve 23 . Approximately half of the motor neurons in the ventral horn degenerated on the side ipsilateral to the injection by 1 week after this manipulation (P < 0.0005, paired Student's t test; Supplementary  Fig. 4a-c) . However, neither the morphology nor the proliferation rate of NG2 + cells, as assessed by NG2 and Ki67 immunoreactivity, respectively, was altered by this loss of motor neurons ( Supplementary  Fig. 4b,d ), suggesting that acute motor neuron death is not sufficient to induce activation and recruitment of these progenitors.
To determine when oligodendrocytes begin to exhibit abnormalities in ALS mice, we examined their morphology in Mobp-EGFP; SOD1 (G93A) and Mobp-EGFP mice at different stages of disease. Oligodendrocyte somata (EGFP + Olig2 + ) in the spinal cord of Mobp-EGFP mice had a consistent oval shape (Fig. 5a,b and Supplementary Fig. 3 ). In the spinal cord of end stage Mobp-EGFP; SOD1 (G93A) mice, there was a marked increase in irregularly shaped EGFP + structures, many of which were Olig2 − and lacked nuclei (Fig. 5a,b and Supplementary Fig. 5a ), reminiscent of the fragmentation that occurs during apoptotic cell death 24 . Despite this increase in EGFP + structures, the density of EGFP + Olig2 + oligodendrocytes in end stage SOD1 (G93A) mice was not different from that in control mice (control, 1,137 ± 61 cells; SOD1 (G93A), 1,233 ± 73 cells per mm 2 ; n = 9 sections, 3 mice per group, P = 0.33, Student's t test), consistent with results obtained using CC1 immunoreactivity (Fig. 2i) . We also observed irregularly shaped EGFP + oligodendrocyte somata with reduced or absent Olig2 immunoreactivity at earlier stages of disease (Supplementary Fig. 5b,c) . To evaluate the progressive nature of these changes, we measured the area of EGFP + cell fragments following digital subtraction of EGFP + Olig2 + somata (Supplementary Fig. 5d ). EGFP + cellular fragments were evident at P90 in SOD1 (G93A) mice, but were rarely observed in aged matched controls (volume of fragments: control, 10 ± 5.1 µm 3 ; SOD1 (G93A), 131 ± 13 µm 3 ; P < 7.9 × 10 −6 , Student's t test; Fig. 5c ), indicating that pathological alterations in oligodendrocytes are widespread by the time mice begin to show behavioral manifestation of disease.
Myelin deficits in spinal cord gray matter of ALS mice
The accelerated turnover (that is, death and subsequent regeneration) and abnormal structure of oligodendrocytes in ALS mice suggests that the state of myelination in gray matter may be altered in disease. Indeed, electron microscopic analysis of ventral gray matter revealed that the proportion of ultrastructurally normal axons with immature myelin, as evidenced by the presence of a thick layer of oligodendrocyte cytoplasm between the axon and initial myelin wraps, was 49% higher in end stage SOD1 (G93A) mice than in age-matched controls (percentage of axons with immature myelin: control, 9.3 ± 1.2%; SOD1 (G93A), 13.9 ± 1.0%; n = 3 mice per group, P < 0.01, unpaired Student's t test; Fig. 6a ), suggesting that viable, uninjured axons were being remyelinated in ALS mice. Axons with disorganized microtubules, electron dense bodies and spheroids surrounded by swollen, electron dense myelin, typical of Wallerian degeneration 17 , were also common in the ventral gray matter of SOD1 (G93A) mice (Supplementary Fig. 6a ). Moreover, myelin basic protein (MBP) immunoreactivity was more diffuse in ventral gray matter of SOD1 (G93A) mice at end stage and was often not colocalized with EGFP, in contrast with the filamentous EGFP + processes present in npg a r t I C l e S Mobp-EGFP mice (Fig. 6b) . Axons with mature myelin had thicker myelin sheaths and lower g ratios (ratio of axon diameter to myelin diameter) in SOD1 (G93A) mice than those in control mice ( Supplementary  Fig. 6b-d) , possibly reflecting shrinkage of axons from metabolic stress or abnormal patterns of gene expression in oligodendrocytes.
To determine the structure of oligodendrocytes generated after P60, we used membrane-anchored EGFP Cre reporter mice (ROSA26-mEGFP, mT/mG) to visualize their fine cellular processes 5 . Pdgfra-creER; ROSA26-mEGFP; SOD1 (G93A) and Pdgfra-creER; ROSA26-mEGFP mice were injected with 4HT at P60 and analyzed 2 months later (Fig. 6c) . In control mice (P60+60), numerous thin, unbranched EGFP + processes were visible throughout the ventral gray matter, consistent with the morphology of normal internodal segments ( Fig. 6d) . Although oligodendrocytes generated after P60 in a c SOD1 (G93A) mice also expressed CC1 ( Fig. 2c-e) , their processes were highly branched with numerous varicosities (Fig. 6d) ; the processes of these newly generated oligodendrocytes often did not colocalize with MBP, in contrast with oligodendrocyte processes in control mice (Fig. 6e) . Immunogold electron microscopic labeling of EGFP revealed that adult-born oligodendrocytes in SOD1 (G93A) mice were frequently associated with degenerating axons (Fig. 6f,g) , suggesting that these axons had experienced at least one round of demyelination and remyelination. In addition, there were many irregularly shaped, immunogold-positive structures in SOD1 (G93A) mice that were not associated with axons ( Fig. 6h) , reminiscent of the oligodendrocyte fragmentation observed through confocal microscopy (Fig. 5b) . Thus, oligodendrocytes generated in this disease context do not achieve the normal structure of myelinating oligodendrocytes. Western blot analysis revealed that the protein levels of myelinassociated proteins MBP, CNPase (2′,3′-cyclic nueotide-3′-phosphodiesterase) and MOG (myelin-oligodendrocyte glycoprotein) progressively decreased with age ( Supplementary Fig. 7a,b) , with the mature myelin protein MOG exhibiting the earliest decline by P60; this reduction in myelin was most prominent in ventral gray matter ( Supplementary  Fig. 7c) . The decrease in myelin protein expression was accompanied by a concomitant increase in PDGFαR expression in both symptomatic (P90) and end stage mice (Supplementary Fig. 7a,b) . Although NG2 + cell density in the spinal cord of SOD1 (G93A) mice was not significantly changed (P > 0.05) at earlier stages of disease ( Fig. 2f-h) , the increased expression of PDGFαR from P90 is consistent with progressive mobilization of these progenitors in response to the loss of oligodendrocytes [25] [26] [27] . Together, these findings indicate that myelination is disrupted in the spinal cord ventral gray matter of ALS mice.
Reactive NG2 + cells and focal gray matter demyelination in ALS NG2 + cells are abundant in the human CNS and are likely to be major contributors to the regeneration of oligodendrocytes in demyelinating diseases such as multiple sclerosis 28 . To determine whether NG2 + cells also undergo reactive changes in ALS patients, we carried out immunohistochemistry on human motor cortices. We analyzed motor cortex rather than spinal cord, as this tissue is better preserved in human autopsies, which is required to preserve the NG2 proteoglycan. Sections were immunostained for the microglial antigen Iba1 to distinguish NG2 + glial cells from NG2-expressing macrophages and microglia that often appear in chronic disease and CNS injury 29, 30 . NG2 immunoreactivity was markedly higher in the motor cortex of ALS patients than in either motor cortex from non-ALS subjects (control, 106.2 ± 5.3%; ALS, 200.2 ± 9.4%; P < 0.0001, unpaired Student's t test) or occipital cortex from the same patients, as determined by the intensity of NG2 immunoreactivity ( Fig. 7a and Supplementary  Fig. 8a,b) . Although NG2 + Iba1 + cells were observed in both control and ALS motor cortex, thicker NG2 + processes that exhibited signs of hypertrophy in ALS tissue did not express Iba1 ( Supplementary  Fig. 8a) , indicating that NG2 + glial cells exhibit reactive changes in regions of brain in which motor neurons degenerate in ALS.
To assess whether these changes in NG2 + cells also were associated with degeneration of oligodendrocytes in gray matter, we examined the integrity of myelin in motor cortex and spinal cord of sporadic and familial ALS patients. Myelin staining (Luxol fast blue) and MBP immunolabeling revealed areas of focal loss of myelin in motor cortex gray matter of ALS patients that were not observed in control patients (Fig. 7b,c and Supplementary Table 1) . Moreover, in addition to the well-described reduction in myelination of corticospinal tracts, myelin was also reduced in ventral horn gray matter of the spinal cord from ALS patients (Fig. 7d) . To quantify the extent of myelin loss, we determined MBP and CNPase abundance in randomly sampled regions of primary motor cortex gray matter (Fig. 7e,f and Supplementary Fig. 8c,d) , as well as in spinal cord ventral gray matter (Fig. 7g,h) . MBP expression was significantly lower (P < 0.001 and P < 0.05 for motor cortex and spinal cord ventral horn, respectively) in most ALS patients relative to controls, whereas CNPase levels were substantially reduced in one patient and trended lower in a second patient. Furthermore, the (a) Sections of motor cortex gray matter from control and ALS patients showing immunoreactivity to NG2. NG2 + cells are highlighted by arrowheads (see Supplementary Fig. 8a ). Images were acquired from cortical layers IV and V. Scale bar represents 20 µm. (b) Luxol fast blue staining of motor cortices from control subjects and ALS patients. npg a r t I C l e S reduction in expression of myelin proteins was greater in motor cortices than in occipital cortices from the same ALS patients, consistent with motor cortex specific lesions (Supplementary Fig. 8c,d) . Although it is not yet possible in these tissues to determine the relative contributions of primary oligodendrocyte death and secondary oligodendrocyte death because of Wallerian degeneration, these results indicate that demyelination of gray matter regions in which motor neurons are located is a common feature of human ALS.
Mutant SOD1 deletion from oligodendroglia reduces disease
Oligodendrocytes are vulnerable to damage through cell-autonomous expression of genes linked to neurodegeneration 31, 32 , particularly aggregation-prone proteins, raising the possibility that expression of mutant SOD1 in oligodendrocytes may impair their function and promote motor neuron degeneration. To determine whether there is an oligodendroglial contribution to disease in ALS, we selectively removed mutant human SOD1 (G37R) from NG2 + cells in Pdgfra-creER; loxSOD1(G37R) mice 2 . Administration of 4HT to these mice at P18 and P30 markedly delayed disease onset by 69 d (median, P = 0.0003), delayed early disease by 83 d (median, P = 0.001) and prolonged survival by more than 130 d (median, P < 0.001) (Fig. 8a,b) . Consistent with this delay in disease, these mice exhibited less astrogliosis and microglial activation in the spinal cord ( Supplementary  Fig. 9a) . The time from symptom onset to death (that is, disease duration) was not altered by removal of SOD1 (G37R) from oligodendroglia (−4HT, 180 ± 17 d; +4HT, 209 ± 15 d; mean ± s.e.m., n = 12 mice per group, P = 0.246, Mann Whitney test), indicating that the prolonged survival of these mice resulted primarily from a delay in disease onset. This manipulation decreased SOD1 (G37R) gene expression in the NG2 + cell population by ~43%, as determined by quantitative PCR from isolated NG2 + cells (data not shown), but preserved its expression in motor neurons (Supplementary Fig. 9b ). Although this approach had little effect on overall tissue levels of SOD1 (G37R) (Supplementary Fig. 9c,d) , consistent with the relatively small number of NG2 + cells present (2-5% of all neural cells in the spinal cord) 33 , it presumably affected all oligodendrocytes generated from SOD1 (G37R)-deleted NG2 + cells.
Previous studies have found that oligodendrocytes present at end stage of disease in SOD1 (G93A) mice express much less MCT1 (ref. 9) . Given that oligodendrocytes provide metabolic support to axons via this transporter and that its expression is downregulated in SOD1 (G93A) mice 9 , we evaluated MCT1 expression in SOD1 (G37R)deleted mice. Removal of SOD1 (G37R) from oligodendroglia helped preserve MCT1 expression in some mice at early stages of disease ( Fig. 8c) . Together, these data indicate that expression of mutant SOD1 in NG2 + cells and their oligodendrocyte progeny has a deleterious effect on motor neuron survival, and suggest that one negative consequence of mutant SOD1 expression in oligodendrocytes is to diminish their capacity to provide metabolic support to neurons.
DISCUSSION
Oligodendrocytes form myelin sheaths around axons in the CNS that enable rapid conduction of action potentials at minimal energetic cost. However, the perception that oligodendrocytes are primarily structural elements has been challenged by recent evidence that they also provide metabolic support to neurons by transferring glycolytic intermediates 34 through the monocarboxylic transporter MCT1 (ref. 9) . Motor neurons in the spinal cord depend on this transporter for survival, suggesting that oligodendrocyte integrity affects motor neuron fate. We found extensive degeneration of gray matter oligodendrocytes in ALS mice that began before the onset of behavioral symptoms of disease. Although NG2 + progenitor cells are mobilized to regenerate oligodendrocytes, oligodendrocytes generated in later stages of disease exhibited aberrant morphologies and failed to restore myelin (Supplementary Fig. 10) . A reduction in gray matter myelin and reactive changes in NG2 + cells were frequently observed in the motor cortex and spinal cord of ALS patients, indicating that degeneration of gray matter oligodendrocytes is prevalent in human ALS. Selective deletion of mutant SOD1 protein from oligodendroglia delayed disease onset and prolonged survival in mice, pointing to a key role for these cells in the precipitation of disease in ALS. Together, these results suggest that the marked loss of gray matter oligodendrocytes in ALS, and the inability to restore oligodendrocyte function, accelerates injury to vulnerable motor neurons.
There is accumulating evidence that ALS is not strictly a disease of motor neurons [1] [2] [3] 35, 36 . Selective removal of mutant SOD1 (G37R) from motor neurons slowed disease onset, but did not alter disease progression, indicating that expression of this mutant gene in other cell types is sufficient to cause motor neuron death 2 . In particular, astrocytes appear to be important contributors to disease, as there is a marked reduction in astrocyte glutamate transporter expression in mouse models of ALS 35 and ALS patients 37 , astrocytes from SOD1 (G93A) mice secrete factors that are toxic to motor neurons 38 , and removal of mutant SOD1 from astrocytes delays microglial activation and extends animal survival 3 . However, expression of mutant SOD1 only in astrocytes is not sufficient to induce disease 39 , indicating that astrocyte dysfunction combines with other cellular alterations to accelerate the death of motor neurons. Supplementary Figure 11 . npg a r t I C l e S The consequences of mutant protein expression in oligodendrocytes has been examined using chimeric mice in which oligodendrocytes and motor neurons express mutant SOD1, while all other cells expressed either wild-type or mutant SOD1 (ref. 40) . Notably, most of these mice survived substantially longer than mice that expressed SOD1 (G37R) ubiquitously, and did not exhibit motor neuron degeneration at the time of death, suggesting that alterations in cells other than motor neurons and oligodendrocytes are critical for determining disease onset. Nevertheless, we found that selective removal of this mutant protein from oligodendrocyte progenitors markedly slowed disease progression. It is possible that ALS-linked gene mutations render oligodendrocytes more vulnerable to stresses created by abnormalities in other cells, and that oligodendrocyte degeneration is the critical event that triggers motor neuron degeneration. Indeed, oligodendrocyte vulnerability may be exacerbated by the presence of proinflammatory cytokines such as interferon-γ 41 , which at high levels induces apoptosis of oligodendrocytes 42 . Expression of mutant SOD1 in oligodendrocyte progenitors may also induce long-term changes in gene expression that increase the vulnerability of oligodendrocytes.
Mutations in genes linked to ALS, such as Sod1 (SOD1), Tardbp (TDP-43) and Fus (FUS), cause the formation of protein aggregates, often leading to endoplasmic reticulum stress that can induce apoptosis. Ubiquitinated protein aggregates containing TDP-43 have been observed in oligodendrocytes in patients with frontotemporal lobar degeneration 43 , and other mutant proteins, such as α-synuclein 44 and tau 45 , accumulate in oligodendrocytes in patients with multiple system atrophy and other types of frontotemporal dementia (FTD). These observations raise the possibility that expression of aggregation-prone mutant proteins in oligodendrocytes compromises their ability to provide adequate support to neurons. Selective overexpression in oligodendrocytes of a mutant form of tau (P301L) associated with a human form of FTD (frontotemporal dementia and parkisonism linked to chromosome 17, FTDP-17) leads to formation of filamentous tau + inclusions in these cells, eventual oligodendrocyte degeneration and reduced myelin 31 . These animals also exhibited impaired axonal transport, muscle atrophy and hind limb weakness, which are suggestive of motor neuron degeneration. We observed that oligodendrocyte degeneration in the spinal cord of ALS mice and demyelination in the brains of ALS patients were prominent in gray matter regions near motor neurons, indicating that oligodendrocytes in these regions are more susceptible to disease-related stresses. Notably, previous studies have shown that oligodendrocytes in the spinal cord gray matter are particularly vulnerable to endoplasmic reticulum stress when proteolipid protein, a component of myelin, is overexpressed 46 . Thus, the regional bias in oligodendrocyte vulnerability may depend more on metabolic demand, which is related to the type of associated neuron, than on the need for myelination.
Although some oligodendrocyte degeneration may be a secondary consequence of motor neuron death in ALS, motor axons represent only a minor portion of myelinated fibers in spinal cord gray matter. Given that each oligodendrocyte in the spinal cord forms on average ~25 internodal segments 47 , each with a different axon, it seems likely that there would be sufficient remaining axons to promote oligodendrocyte survival, unless dying motor neurons produce pro-apoptotic signals. Furthermore, enhancing oligodendrogenesis without appropriate target axons to myelinate would appear maladaptive. The increase in ultrastructurally normal axons with immature myelin sheaths in ventral gray matter of end stage SOD1 (G93A) mice (Fig. 6a) suggests that oligodendrocytes attempt to remyelinate viable axons, rather than simply degenerate as a result of axon loss. Our results also indicate that selective degeneration of motor neurons is not sufficient to enhance the proliferation of NG2 + cells in the spinal cord (Supplementary Fig. 4) , which is expected to occur if new oligodendrocytes are being formed 17, 23, 24 . Conversely, degeneration of oligodendrocytes and demyelination are sufficient to induce neuronal apoptosis, as seen after genetically induced oligodendrocyte ablation 25, 26 and in multiple sclerosis 48 . Thus, oligodendrocyte loss is expected to have a negative effect on the integrity and survival of motor neurons during the course of disease.
When do oligodendrocytes begin to degenerate in ALS? Although proliferation of NG2 + cells was enhanced well before behavioral onset of disease, their density did not increase, as there was a concomitant increase in the proportion of cells undergoing differentiation. If this increase in oligodendrogenesis compensates for cells that are lost or injured, as would be expected from the maintenance of oligodendrocyte number (Fig. 2) , then oligodendrocyte degeneration is a very early event in the disease process. Despite the continuous regeneration of oligodendrocytes, the proportion of incompletely myelinated axons increased, myelin levels were reduced and oligodendrocytes failed to express MCT1, indicating that their maturation was impaired. In addition, adult-born oligodendrocytes exhibited morphological characteristics of apoptosis, suggesting that their turnover was accelerated. This expanding cycle of proliferation, differentiation and death in the oligodendrocyte lineage in ALS may accelerate damage to vulnerable motor neurons by consuming resources and triggering reactive changes in other glial cells (Supplementary Fig. 10) .
The degeneration of oligodendrocytes and impaired maturation of oligodendrocyte progenitors in ALS share similarities to progressive forms of multiple sclerosis, where impaired remyelination following immune-mediated attack of oligodendrocytes leads to neuronal degeneration. Indeed, there is increasing appreciation of gray matter demyelination in multiple sclerosis 49 . Thus, therapeutic approaches that are being developed to treat multiple sclerosis, based on promotion of oligodendrocyte survival or enhancement of oligodendroglial metabolic support to neurons, may be helpful for preventing motor neuron degeneration in ALS.
METhODS
Methods and any associated references are available in the online version of the paper.
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